Overview

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

Status:
Withdrawn
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to test the effect of the combination of valproate in combination with imatinib with an aim of achieving a maximal molecular response as the primary goal.
Phase:
Phase 2
Details
Lead Sponsor:
New Mexico Cancer Care Alliance
Treatments:
Imatinib Mesylate
Valproic Acid